Herceptin® (Trastuzumab) is the only FDA-approved therapeutic for HER2 protein overexpressing metastatic breast cancer. Herceptin is a therapy for women with metastatic breast cancer whose tumors have too much HER2 protein. For patients with this disease, Herceptin is approved for first-line use in combination with paclitaxel, and as a single agent for those who have received one or more chemotherapy regimens.

Herceptin is not a chemotherapy. It is a monoclonal antibody (sometimes called biologic therapy).

Highest Dev Status	Launched
Therapeutic Area	Oncology
Potential Indications	Please Login
Identified Action Mechanisms	6
Drug Website	http://www.herceptin.com
Literature	NCBI